LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "mutation positive" as a keyword



Photo from wikipedia

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies

Sign Up to like & get
recommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"

DOI: 10.1002/cpdd.773

Abstract: Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation–positive unresectable or metastatic melanoma and Erdheim‐Chester disease. This phase 1, open‐label, single‐arm study was designed to estimate absolute bioavailability of… read more here.

Keywords: mutation positive; bioavailability; absolute bioavailability; patients brafv600 ... See more keywords

Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1–PPP1CB complexes

Sign Up to like & get
recommendations! Published in 2018 at "Human Genetics"

DOI: 10.1007/s00439-018-1951-7

Abstract: RASopathies are a group of developmental disorders caused by mutations in genes that regulate the RAS/MAPK pathway and include Noonan syndrome (NS), Costello syndrome, cardiofaciocutaneous syndrome and other related disorders. Whole exome sequencing studies recently… read more here.

Keywords: raf1 ppp1cb; noonan syndrome; mutation positive; ppp1cb ... See more keywords

Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma

Sign Up to like & get
recommendations! Published in 2018 at "Medical Oncology"

DOI: 10.1007/s12032-018-1082-y

Abstract: The epidermal growth factor receptor (EGFR) mutation status has become one of the most important factors in the treatment of non-small cell lung cancer. However, the relationship between EGFR mutation and the histologic subtype of… read more here.

Keywords: egfr mutation; mutation positive; epidermal growth; adenocarcinoma ... See more keywords
Photo from wikipedia

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

Sign Up to like & get
recommendations! Published in 2021 at "Lung cancer"

DOI: 10.1016/j.lungcan.2021.02.025

Abstract: OBJECTIVES To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing ARCHER 1050 trial. MATERIALS AND METHODS In this ongoing, randomized,… read more here.

Keywords: egfr mutation; first line; mutation positive; asian patients ... See more keywords

J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib

Sign Up to like & get
recommendations! Published in 2025 at "Future Oncology"

DOI: 10.1080/14796694.2025.2514423

Abstract: ABSTRACT Aim The J-REGISTER study assessed outcomes and subsequent treatment in patients with EGFR mutation-positive NSCLC treated with first-line afatinib, including patients with uncommon EGFR mutations. Patients & methods This retrospective study assessed 805 patients… read more here.

Keywords: mutation positive; treatment; patients egfr; egfr mutation ... See more keywords

Public assistance and survival equality in patients with EGFR mutation-positive lung cancer

Sign Up to like & get
recommendations! Published in 2024 at "Japanese Journal of Clinical Oncology"

DOI: 10.1093/jjco/hyae167

Abstract: Abstract Background Disparities in public assistance or the urbanization level of a residential region can affect cancer treatment outcomes. This study aimed to investigate whether these factors affect the overall survival (OS) of patients with… read more here.

Keywords: cancer; mutation positive; assistance; public assistance ... See more keywords

Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer

Sign Up to like & get
recommendations! Published in 2024 at "Japanese Journal of Clinical Oncology"

DOI: 10.1093/jjco/hyae176

Abstract: Abstract Introduction Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including both sensitizing and T790M resistance… read more here.

Keywords: mutation positive; efficacy; growth factor; mutation ... See more keywords

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review

Sign Up to like & get
recommendations! Published in 2022 at "Medicine"

DOI: 10.1097/md.0000000000029682

Abstract: Rationale: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is known to develop during these… read more here.

Keywords: cell; mutation; treatment; transformation ... See more keywords
Photo from wikipedia

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma

Sign Up to like & get
recommendations! Published in 2021 at "Thoracic Cancer"

DOI: 10.1111/1759-7714.13869

Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R, comprise 7%–23%… read more here.

Keywords: afatinib treatment; mutation positive; treatment; epidermal growth ... See more keywords

Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib

Sign Up to like & get
recommendations! Published in 2022 at "Thoracic Cancer"

DOI: 10.1111/1759-7714.14608

Abstract: Clinically measurable factors affecting the progression‐free survival (PFS) of patients receiving osimertinib as first‐line therapy for epidermal growth factor receptor (EGFR) mutation‐positive advanced non‐small cell lung cancer (NSCLC) have not yet been established. read more here.

Keywords: free survival; progression free; first line; egfr mutation ... See more keywords

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies

Sign Up to like & get
recommendations! Published in 2023 at "Thoracic Cancer"

DOI: 10.1111/1759-7714.14858

Abstract: The most common driver gene mutation in patients with non‐small‐cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR‐tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC… read more here.

Keywords: therapy egfr; targeted therapy; egfr mutation; mutation ... See more keywords